Restructuring and Contract Terminaiton Charges, Net (Tables)

12 Months Ended

Jan. 03, 2021

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs [Table Text Block]

The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions implemented during fiscal years 2020, 2019 and 2018 in continuing operations:

	Workforce Reductions					Closure of Excess Facility				Total		(Expected) Date Payments Substantially Completed by
	Headcount Reduction	Diagnostics		Discovery & Analytical Solutions		Diagnostics		Discovery & Analytical Solutions				Severance	Excess Facility
	(In thousands, except headcount data)
Q3 2020 Plan	23	$	901	$	2,080	$	—	$	—	$	2,981	Q2 FY2021	—
Q1 2020 Plan	32	1,134		2,312		682		92		4,220		Q4 FY2020	Q1 FY2022
Q4 2019 Plan	22	2,404		177		—		—		2,581		Q3 FY2020	—
Q3 2019 Plan	259	2,641		11,156		—		—		13,797		Q2 FY2020	—
Q2 2019 Plan	44	1,129		4,461		—		—		5,590		Q1 FY2020	—
Q1 2019 Plan	105	1,459		6,001		—		—		7,460		Q4 FY2019	—
Q4 2018 Plan	1	—		348		—		—		348		Q1 FY2019	—
Q3 2018 Plan	61	618		1,146		—		—		1,764		Q4 FY2019	—
Q1 2018 Plan	47	902		5,096		—		—		5,998		Q4 FY2019	—

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

The following table summarizes the Company's restructuring accrual balances and related activity by restructuring plan, as well as other accrual balances and related activity, during fiscal years 2020, 2019 and 2018 in continuing operations:

	Balance at December 31, 2017		2018 Charges and Changes in Estimates, Net		2018 Amounts Paid		Balance at December 30, 2018		2019 Charges and Changes in Estimates, Net		2019 Amounts Paid		Balance at December 29, 2019		2020 Charges and Changes in Estimates, Net		2020 Amounts Paid		Balance at January 3, 2021
Severance:
Q3 2020 Plan	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	2,981	$	(1,814)	$	1,167
Q1 2020 Plan	—		—		—		—		—		—		—		3,446		(2,574)		872
Q4 2019 Plan(1)	—		—		—		—		2,581		(1,692)		889		(386)		(454)		49
Q3 2019 Plan(2)	—		—		—		—		13,797		(7,486)		6,311		(2,025)		(2,779)		1,507
Q2 2019 Plan(3)	—		—		—		—		5,590		(3,701)		1,889		(376)		(1,241)		272
Q1 2019 Plan(4)	—		—		—		—		7,483		(5,354)		2,129		(867)		(669)		593
Q4 2018 Plan	—		348		—		348		3		(351)		—		—		—		—
Q3 2018 Plan	—		2,054		(639)		1,415		(77)		(1,314)		24		—		—		24
Q1 2018 Plan(5)	—		5,998		(4,389)		1,609		(1,069)		(282)		258		(255)		—		3
Facility:
Q1 2020 Plan	—		—		—		—		—		—		—		774		(380)		394
Previous Plans(6)	10,921		(1,998)		(6,252)		2,671		(159)		(1,147)		1,365		219		(482)		1,102
Restructuring	10,921		6,402		(11,280)		6,043		28,149		(21,327)		12,865		3,511		(10,393)		5,983
Contract Termination	3,048		4,742		(7,653)		137		452		(401)		188		212		(82)		318
Other Costs	—		—		—		—		827		—		827		4,290		(3,119)		1,998
Total Restructuring and Other Liabilities	$	13,969	$	11,144	$	(18,933)	$	6,180	$	29,428	$	(21,728)	$	13,880	$	8,013	$	(13,594)	$	8,299

____________________________

(1)During fiscal year 2020, the Company recognized pre-tax restructuring reversals of $0.3 million in the Discovery & Analytical Solutions segment and $0.1 million in the Diagnostics segment related to lower than expected costs associated with workforce reductions for the Q4 2019 Plan.

(2)    During fiscal year 2020, the Company recognized pre-tax restructuring reversals of $1.9 million in the Discovery & Analytical Solutions segment and $0.1 million in the Diagnostics segment related to lower than expected costs associated with workforce reductions for the Q3 2019 Plan.

(3)During fiscal year 2020, the Company recognized pre-tax restructuring reversals of $0.4 million in the Discovery & Analytical Solutions segment related to lower than expected costs associated with workforce reductions for the Q2 2019 Plan.

(4)During fiscal year 2020, the Company recognized pre-tax restructuring reversals of $0.9 million in the Discovery & Analytical Solutions segment related to lower than expected costs associated with workforce reductions for the Q1 2019 Plan.

(5)During fiscal year 2020, the Company recognized pre-tax restructuring reversals of $0.2 million in the Discovery & Analytical Solutions segment and $0.1 million in the Diagnostics segment related to lower than expected costs associated with workforce reductions for the Q1 2018 Plan.

(6)During fiscal year 2020, the Company recognized pre-tax restructuring reversals of $0.1 million in each of the Discovery & Analytical Solutions and Diagnostics segments related to lower than expected costs associated with workforce reductions for the Previous Plans.